Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Friday. The firm issued a sell rating on the stock.

A number of other research firms also recently issued reports on SYRS. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ:SYRS opened at $0.21 on Friday. The firm has a market cap of $5.67 million, a price-to-earnings ratio of -0.07 and a beta of 1.31. The firm has a fifty day moving average price of $0.23 and a 200 day moving average price of $1.95. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the company posted ($1.35) EPS. As a group, research analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insiders Place Their Bets

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC grew its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,575 shares of the company’s stock after acquiring an additional 139,400 shares during the period. Exome Asset Management LLC owned 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent reporting period. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.